Ziopharm Oncology Inc (ZIOP) 10.77 $ZIOP
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 6.78 (-0.32), ZIOP: 10.77 (-0.84), XON: 45.37 (-0.93)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019
M2 - Tue Mar 31, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9z3pb/global_small_cell) has announced the addition of the "Global Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.6% over the period 2014-2019 The report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The strategic alliances among vendors are an important trend being witnessed in the market. These are expected to give these market players a competitive edge over the others. The companies can leverage their strengths, which is expected to prove mutually beneficial. According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Small cell lung cancer advances very fast, and the detection rate is low at the localized stage. Current treatment options cannot cure the disease; hence, the mortality rate is high. Therefore, drugs that cause disease remission in patients are expected to drive the growth of the market significantly. Further, the report states that the high cost of treatments is a major factor that restricts the growth of the market. Drugs for treatment of the cancer are expensive and hence, get poor response from patients. Hospital costs add to the cost of treatment. The co-morbidities associated with small cell lung cancer also need to be treated, which increases the cost of treatment. Key Vendors - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Oncology Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/k9...small_cell
ZIOP: 10.77 (-0.84), GSK: 46.15 (-1.05), BMY: 64.50 (-1.26)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.77 (-0.84), XON: 45.37 (-0.93)
Ziopharm up 15% on Intrexon/Merck Serono deal
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:26AM CDT
ZIOP: 10.77 (-0.84)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.50 (-0.01), CRMD: 9.84 (+1.14), NCFT: 25.57 (-0.10), LEJU: 7.96 (-0.51), CTRX: 59.54 (-0.29), ZIOP: 10.77 (-0.84), ADXS: 14.44 (+1.00), CNAT: 7.12 (-0.41), XON: 45.37 (-0.93), BBEP: 5.48 (-0.07), ADMP: 3.94 (+0.11), CLDN: 18.94 (-2.73), ASPX: 100.27 (-0.09), HPTX: 45.90 (-0.08), GENE: 5.27 (+0.33), SYN: 2.19 (-0.10), ICEL: 16.43 (+0.01), HZNP: 25.97 (+0.19), OHRP: 2.54 (-0.27), SFUN: 6.00 (-0.35), CNET: 1.61 (-0.05)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.77 (-0.84), MRK: 57.48 (-0.86), XON: 45.37 (-0.93)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 372.10 (-2.49), ZIOP: 10.77 (-0.84), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), INXN: 28.20 (+0.14), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), LEN: 51.81 (+0.32), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), XHB: 36.86 (+0.01), P: 16.21 (-0.18), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), PHM: 22.23 (-0.21), DIA: 177.58 (-1.81), ITB: 28.23 (-0.03), JUNO: 60.66 (-0.09), IWM: 124.37 (-0.40), KBH: 15.62 (-0.04), AAPL: 124.43 (-1.94), ZU: 12.99 (-0.38), BABA: 83.24 (-0.66)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.77 (-0.84), ESPR: 92.60 (+0.56), NVAX: 8.27 (-0.37), PFE: 34.79 (-0.21), XON: 45.37 (-0.93)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.77 (-0.84), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 11.88 (+0.01), ADXS: 14.44 (+1.00), VRTX: 117.97 (-3.28), ZIOP: 10.77 (-0.84), ARWR: 6.76 (-0.24)
Investors Remain Optimistic on Stocks; Trouble Brewing for Tiffany & Co.
at The Street - Fri Mar 20, 1:42PM CDT
The CNBC ‘Fast Money Halftime’ traders say that despite volatility, stock prices are likely to continue rising.
EWI: 14.80 (-0.18), ZIOP: 10.77 (-0.84), EWG: 29.84 (-0.52), EWQ: 25.98 (-0.40), EWP: 34.78 (-0.25), TIF: 88.01 (-0.58), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), HEWG: 28.54 (-0.35), VLO: 63.62 (-0.14), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), EWU: 18.01 (-0.31), DIA: 177.58 (-1.81), EWGS: 39.41 (-0.62), MCD: 97.44 (-0.44), RSX: 17.03 (-0.21), IWM: 124.37 (-0.40), FXI: 44.40 (-0.34)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 120.77 (-3.12), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), CNDO: 3.85 (+0.31), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.77 (-0.84), AR: 35.32 (+0.11), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), ROST: 105.36 (-0.38)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 35.32 (+0.11), ZIOP: 10.77 (-0.84), HALO: 14.28 (+0.28), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), JUNO: 60.66 (-0.09), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), ROST: 105.36 (-0.38)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 188.77 (-1.80), ZIOP: 10.77 (-0.84), AR: 35.32 (+0.11), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), FB: 82.21 (-0.98), WFC: 54.40 (-0.37), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), PLKI: 59.82 (-0.92), SBUX: 94.70 (-1.28), ESPR: 92.60 (+0.56), RCPT: 164.89 (+4.84), CRZO: 49.65 (-0.19), CRL: 79.29 (-0.54), MMP: 76.71 (-2.33), ROST: 105.36 (-0.38), REGN: 451.48 (-8.30)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 129.07 (-4.87), JNJ: 100.60 (-0.95), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.19 (-0.10), ZIOP: 10.77 (-0.84), UNIS: 4.01 (+0.07), FCSC: 4.51 (+0.17), XON: 45.37 (-0.93), MNKD: 5.20 (-0.13)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 46.33 (-0.75), NWBO: 7.37 (-0.09), ZIOP: 10.77 (-0.84), PCYC: 255.95 (-0.48), CVM: 1.05 (+0.01), PFE: 34.79 (-0.21), CLDX: 27.87 (+0.03), IMGN: 8.95 (+0.43), BMY: 64.50 (-1.26), RIGL: 3.57 (+0.22), INO: 8.16 (-0.17), KITE: 57.68 (-2.30), LH: 126.09 (-1.19), ABBV: 58.54 (+0.30), PBYI: 236.11 (-3.65)
ZIOPHARM Oncology (ZIOP) Downgraded From Hold to Sell
at The Street - Wed Mar 11, 2:00PM CDT
ZIOPHARM Oncology (ZIOP) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D-.
ZIOP: 10.77 (-0.84)
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 6.78 (-0.32), ZIOP: 10.77 (-0.84), XON: 45.37 (-0.93)
Global Small Cell Lung Cancer Therapeutics Market 2015-2019
M2 - Tue Mar 31, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9z3pb/global_small_cell) has announced the addition of the "Global Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.6% over the period 2014-2019 The report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The strategic alliances among vendors are an important trend being witnessed in the market. These are expected to give these market players a competitive edge over the others. The companies can leverage their strengths, which is expected to prove mutually beneficial. According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Small cell lung cancer advances very fast, and the detection rate is low at the localized stage. Current treatment options cannot cure the disease; hence, the mortality rate is high. Therefore, drugs that cause disease remission in patients are expected to drive the growth of the market significantly. Further, the report states that the high cost of treatments is a major factor that restricts the growth of the market. Drugs for treatment of the cancer are expensive and hence, get poor response from patients. Hospital costs add to the cost of treatment. The co-morbidities associated with small cell lung cancer also need to be treated, which increases the cost of treatment. Key Vendors - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Oncology Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/k9...small_cell
ZIOP: 10.77 (-0.84), GSK: 46.15 (-1.05), BMY: 64.50 (-1.26)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), CLLS: 34.58 (-0.62), XON: 45.37 (-0.93), AMGN: 159.85 (-4.45), JUNO: 60.66 (-0.09)
Why Shares Intrexon Corp are Skyrocketing Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 30, 11:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Intrexon Corp surged higher...
ZIOP: 10.77 (-0.84), XON: 45.37 (-0.93)
Ziopharm up 15% on Intrexon/Merck Serono deal
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:26AM CDT
ZIOP: 10.77 (-0.84)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 10.50 (-0.01), CRMD: 9.84 (+1.14), NCFT: 25.57 (-0.10), LEJU: 7.96 (-0.51), CTRX: 59.54 (-0.29), ZIOP: 10.77 (-0.84), ADXS: 14.44 (+1.00), CNAT: 7.12 (-0.41), XON: 45.37 (-0.93), BBEP: 5.48 (-0.07), ADMP: 3.94 (+0.11), CLDN: 18.94 (-2.73), ASPX: 100.27 (-0.09), HPTX: 45.90 (-0.08), GENE: 5.27 (+0.33), SYN: 2.19 (-0.10), ICEL: 16.43 (+0.01), HZNP: 25.97 (+0.19), OHRP: 2.54 (-0.27), SFUN: 6.00 (-0.35), CNET: 1.61 (-0.05)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 10.77 (-0.84), MRK: 57.48 (-0.86), XON: 45.37 (-0.93)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 372.10 (-2.49), ZIOP: 10.77 (-0.84), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), INXN: 28.20 (+0.14), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), LEN: 51.81 (+0.32), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), XHB: 36.86 (+0.01), P: 16.21 (-0.18), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), PHM: 22.23 (-0.21), DIA: 177.58 (-1.81), ITB: 28.23 (-0.03), JUNO: 60.66 (-0.09), IWM: 124.37 (-0.40), KBH: 15.62 (-0.04), AAPL: 124.43 (-1.94), ZU: 12.99 (-0.38), BABA: 83.24 (-0.66)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.77 (-0.84), ESPR: 92.60 (+0.56), NVAX: 8.27 (-0.37), PFE: 34.79 (-0.21), XON: 45.37 (-0.93)
Why Ziopharm Oncology, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 1:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology sank by...
ZIOP: 10.77 (-0.84), KITE: 57.68 (-2.30), XON: 45.37 (-0.93), JUNO: 60.66 (-0.09)
Biotech Equities Technical Coverage - ZIOPHARM Oncology, Arrowhead Research, Merrimack Pharma, Vertex Pharma, and Advaxis
PR Newswire - Wed Mar 25, 8:41AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MACK: 11.88 (+0.01), ADXS: 14.44 (+1.00), VRTX: 117.97 (-3.28), ZIOP: 10.77 (-0.84), ARWR: 6.76 (-0.24)
Investors Remain Optimistic on Stocks; Trouble Brewing for Tiffany & Co.
at The Street - Fri Mar 20, 1:42PM CDT
The CNBC ‘Fast Money Halftime’ traders say that despite volatility, stock prices are likely to continue rising.
EWI: 14.80 (-0.18), ZIOP: 10.77 (-0.84), EWG: 29.84 (-0.52), EWQ: 25.98 (-0.40), EWP: 34.78 (-0.25), TIF: 88.01 (-0.58), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), HEWG: 28.54 (-0.35), VLO: 63.62 (-0.14), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), EWU: 18.01 (-0.31), DIA: 177.58 (-1.81), EWGS: 39.41 (-0.62), MCD: 97.44 (-0.44), RSX: 17.03 (-0.21), IWM: 124.37 (-0.40), FXI: 44.40 (-0.34)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 120.77 (-3.12), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), CNDO: 3.85 (+0.31), CLLS: 34.58 (-0.62), JUNO: 60.66 (-0.09)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.77 (-0.84), AR: 35.32 (+0.11), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), ROST: 105.36 (-0.38)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 35.32 (+0.11), ZIOP: 10.77 (-0.84), HALO: 14.28 (+0.28), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), JUNO: 60.66 (-0.09), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), ROST: 105.36 (-0.38)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 188.77 (-1.80), ZIOP: 10.77 (-0.84), AR: 35.32 (+0.11), DRNA: 24.03 (+0.87), AKAM: 71.04 (-0.86), FB: 82.21 (-0.98), WFC: 54.40 (-0.37), LBIO: 12.11 (+0.49), FIVE: 35.57 (+0.08), PLKI: 59.82 (-0.92), SBUX: 94.70 (-1.28), ESPR: 92.60 (+0.56), RCPT: 164.89 (+4.84), CRZO: 49.65 (-0.19), CRL: 79.29 (-0.54), MMP: 76.71 (-2.33), ROST: 105.36 (-0.38), REGN: 451.48 (-8.30)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 129.07 (-4.87), JNJ: 100.60 (-0.95), ZIOP: 10.77 (-0.84), BLCM: 23.17 (+0.52), KITE: 57.68 (-2.30), JUNO: 60.66 (-0.09), NVS: 98.61 (-2.70)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.19 (-0.10), ZIOP: 10.77 (-0.84), UNIS: 4.01 (+0.07), FCSC: 4.51 (+0.17), XON: 45.37 (-0.93), MNKD: 5.20 (-0.13)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 46.33 (-0.75), NWBO: 7.37 (-0.09), ZIOP: 10.77 (-0.84), PCYC: 255.95 (-0.48), CVM: 1.05 (+0.01), PFE: 34.79 (-0.21), CLDX: 27.87 (+0.03), IMGN: 8.95 (+0.43), BMY: 64.50 (-1.26), RIGL: 3.57 (+0.22), INO: 8.16 (-0.17), KITE: 57.68 (-2.30), LH: 126.09 (-1.19), ABBV: 58.54 (+0.30), PBYI: 236.11 (-3.65)
ZIOPHARM Oncology (ZIOP) Downgraded From Hold to Sell
at The Street - Wed Mar 11, 2:00PM CDT
ZIOPHARM Oncology (ZIOP) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D-.
ZIOP: 10.77 (-0.84)
